Why This Gene-Therapy Company's Stock Is Rising 228%
Portfolio Pulse from
Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal, causing its stock to rise by 228%.
November 26, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics is being acquired by Roche for $1.5 billion, leading to a 228% increase in its stock price.
The acquisition by Roche is a significant event for Poseida Therapeutics, directly causing a substantial increase in its stock price. Such acquisitions typically lead to a positive short-term impact on the stock price of the company being acquired.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100